188 related articles for article (PubMed ID: 30706214)
1. Development of BTK inhibitors for the treatment of B-cell malignancies.
Kim HO
Arch Pharm Res; 2019 Feb; 42(2):171-181. PubMed ID: 30706214
[TBL] [Abstract][Full Text] [Related]
2. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
Smith CIE; Burger JA
Front Immunol; 2021; 12():689472. PubMed ID: 34177947
[TBL] [Abstract][Full Text] [Related]
3. Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.
Ponader S; Burger JA
J Clin Oncol; 2014 Jun; 32(17):1830-9. PubMed ID: 24778403
[TBL] [Abstract][Full Text] [Related]
4. The role of Bruton's tyrosine kinase in the immune system and disease.
McDonald C; Xanthopoulos C; Kostareli E
Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
[TBL] [Abstract][Full Text] [Related]
5. Bruton Tyrosine Kinase Degraders in B-Cell Malignancies.
Huynh T; Rodriguez-Rodriguez S; Danilov AV
Mol Cancer Ther; 2024 May; 23(5):619-626. PubMed ID: 38693903
[No Abstract] [Full Text] [Related]
6. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.
Gomez EB; Ebata K; Randeria HS; Rosendahl MS; Cedervall EP; Morales TH; Hanson LM; Brown NE; Gong X; Stephens J; Wu W; Lippincott I; Ku KS; Walgren RA; Abada PB; Ballard JA; Allerston CK; Brandhuber BJ
Blood; 2023 Jul; 142(1):62-72. PubMed ID: 36796019
[TBL] [Abstract][Full Text] [Related]
7. Recent research of BTK inhibitors: Methods of structural design, pharmacological activities, manmade derivatives and structure-activity relationship.
Wang L; Zhang Z; Yu D; Yang L; Li L; He Y; Shi J
Bioorg Chem; 2023 Sep; 138():106577. PubMed ID: 37178649
[TBL] [Abstract][Full Text] [Related]
8. The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies.
Robak P; Witkowska M; Wolska-Washer A; Robak T
Expert Opin Drug Discov; 2023; 18(10):1065-1076. PubMed ID: 37438969
[TBL] [Abstract][Full Text] [Related]
9. The role of noncovalent BTK inhibitors in the era of covalent BTK inhibitors.
Furqan F; Shah NN
Clin Adv Hematol Oncol; 2024 Apr; 22(3):140-147. PubMed ID: 38588273
[TBL] [Abstract][Full Text] [Related]
10. Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist.
Balıkçı E; Marques AMC; Bauer LG; Seupel R; Bennett J; Raux B; Buchan K; Simelis K; Singh U; Rogers C; Ward J; Cheng C; Szommer T; Schützenhofer K; Elkins JM; Sloman DL; Ahel I; Fedorov O; Brennan PE; Huber KVM
J Med Chem; 2024 May; 67(9):7245-7259. PubMed ID: 38635563
[TBL] [Abstract][Full Text] [Related]
11. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies.
Parrondo RD; Iqbal M; Von Roemeling R; Von Roemeling C; Tun HW
Front Immunol; 2023; 14():1239082. PubMed ID: 37954584
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of infection in B-cell lymphoma patients treated with BTK inhibitors].
Wang CM; Liu H; Li LJ; Song J; Wang HQ; Wu YH; Guan J; Xing LM; Wang GJ; Liu H; Qu W; Wang XM; Shao ZH; Fu R
Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):582-586. PubMed ID: 37749040
[No Abstract] [Full Text] [Related]
13. Case report: BTK inhibitors is effective in type II mixed cryoglobulinemia with wild-type MyD88.
Xu M; Xu Y; Yuan L; Shang D; Chen R; Liu S; Li Y; Liu A; Liu R; Wang Q; Ding T; Xie Q; Hao CM
Front Immunol; 2024; 15():1390958. PubMed ID: 38765016
[TBL] [Abstract][Full Text] [Related]
14. Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies.
Song Y; Wu SJ; Shen Z; Zhao D; Chan TSY; Huang H; Qiu L; Li J; Tan TD; Zhu J; Song Y; Huang WH; Zhao W; Liu HSY; Xu W; Chen N; Ma J; Chang CS; Tse EWC
Exp Hematol Oncol; 2023 Oct; 12(1):92. PubMed ID: 37845755
[TBL] [Abstract][Full Text] [Related]
15. A Workflow Combining Machine Learning with Molecular Simulations Uncovers Potential Dual-Target Inhibitors against BTK and JAK3.
Liu L; Na R; Yang L; Liu J; Tan Y; Zhao X; Huang X; Chen X
Molecules; 2023 Oct; 28(20):. PubMed ID: 37894618
[TBL] [Abstract][Full Text] [Related]
16. Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations.
Krämer J; Wiendl H
Curr Opin Neurol; 2024 Jun; 37(3):237-244. PubMed ID: 38533819
[TBL] [Abstract][Full Text] [Related]
17. BTK inhibitor falters in multiple sclerosis trials.
Wood H
Nat Rev Neurol; 2024 May; 20(5):255. PubMed ID: 38594557
[No Abstract] [Full Text] [Related]
18. Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors.
Qi J; Endres S; Yosifov DY; Tausch E; Dheenadayalan RP; Gao X; Müller A; Schneider C; Mertens D; Gierschik P; Wist M; Jebaraj BMC; Stilgenbauer S
Blood Adv; 2023 Oct; 7(19):5698-5702. PubMed ID: 36661329
[No Abstract] [Full Text] [Related]
19. Ibrutinib repurposing: from B-cell malignancies to solid tumors.
Massó-Vallés D; Jauset T; Soucek L
Oncoscience; 2016; 3(5-6):147-8. PubMed ID: 27489860
[No Abstract] [Full Text] [Related]
20. BTK degraders tackle drug resistance.
Villanueva MT
Nat Rev Drug Discov; 2024 Mar; 23(3):173. PubMed ID: 38336888
[No Abstract] [Full Text] [Related]
[Next] [New Search]
